# Spain Dry Age Related Macular Degeneration Market > Spain Dry Age-Related Macular Degeneration (AMD) Market Research Report: Size, Share, Trend Analysis By Stage (early age-related macular degeneration, intermediate age-related macular degeneration, late age-related macular degeneration), By Age Group (above 75 years, above 60 years, above 40 years), By Diagnosis and Treatment (treatment, diagnosis), By Route of Administration (oral, injectables) and By End Userss (hospitals clinics, diagnostic centers, academic research institutes) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 7.52% - **2024:** $ 133.28 Million - **2025:** $ 144.34 Million - **2035:** $ 295.96 Million - **Key Players:** Novartis (ES), Regeneron Pharmaceuticals (ES), Roche (ES), Bayer (ES), Allergan (ES), Apellis Pharmaceuticals (ES), Santen Pharmaceutical (ES), Zeiss (ES), Hoya Corporation (ES) **Report ID:** MRFR/LS/43222-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/spain-dry-age-related-macular-degeneration-market-44902 --- ## Market Summary ## **Spain Dry Age-Related Macular Degeneration (AMD) Market Overview** As per MRFR analysis, the Spain Dry Age-Related Macular Degeneration (AMD) Market Size was estimated at 88.0 (USD Million) in 2023. The Spain Dry Age-Related Macular Degeneration (AMD) Market Industry is expected to grow from 96.0 (USD Million) in 2024 to 218.0 (USD Million) by 2035. The Spain Dry Age-Related Macular Degeneration (AMD) Market CAGR (growth rate) is expected to be around 7.741% during the forecast period (2025-2035). ## **Key Spain Dry Age-Related Macular Degeneration (AMD) Market Trends Highlighted**  The Spain Dry Age-Related Macular Degeneration (AMD) Market is witnessing significant developments driven by an aging population, as nearly 20% of the Spanish populace is over the age of 65, leading to an increased prevalence of AMD. Government initiatives aimed at enhancing eye health awareness and promoting regular eye examinations are vital market drivers, contributing to early detection and treatment. Furthermore, the rise in healthcare spending in Spain has allowed for improved accessibility to advanced diagnostic tools and treatment options for AMD, helping to address unmet medical needs. Opportunities to be explored within this market include telemedicine services, which can increase patient access to specialists, particularly in rural areas where healthcare resources may be limited. Spain is in need of modernization due to the fact that a large portion of the population struggles to access specialized care. Also, the collaboration between healthcare professionals and pharmaceutical companies to develop new therapies has the potential to boost treatment effectiveness. From what I have seen, the modern trend appears to be giving increased attention to personalized medicine, focusing on tailoring treatment to a patient's genetic makeup and lifestyle. With current trends encouraging a shift towards patient-centric care, patients have become more responsible for their treatment regimens, and as a result, many are well-equipped to deal with managing their AMD. Collectively, these trends demonstrate that there is emerging robust attention and strategy toward AMD care in Spain by integrating various levels of patient cognizance, technology, and streamlined treatment options. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Spain Dry Age-Related Macular Degeneration (AMD) Market Drivers** ### **Growing Aging Population in Spain** Spain has one of the highest proportions of elderly individuals in Europe, which is a critical driver for the Spain Dry Age-Related Macular Degeneration (AMD) Market Industry. According to data from the National Institute of Statistics, over 19% of Spain's population is aged 65 or older, and this number is projected to increase significantly in the coming years. The aging population is directly linked to the rising incidence of age-related diseases, including AMD, which the World Health Organization reports is expected to affect approximately 196 million individuals globally by 2020 and is expected to escalate to 288 million by 2040. This demographic shift in Spain, driven largely by improvements in healthcare and increased life expectancy, provides a substantial market opportunity for AMD treatments and management solutions, ultimately fueling growth in the Spain Dry Age-Related Macular Degeneration (AMD) Market. ### **Rising Healthcare Expenditure** The Spanish government's focus on healthcare improvements reflects a significant driver for the Spain Dry Age-Related Macular Degeneration (AMD) Market Industry. Current reports indicate that Spain's healthcare expenditure has grown steadily, with the government allocating around 10% of its GDP to health services. As the country invests in advanced medical treatments and innovative technologies, the increased funding allows for improved AMD diagnosis and treatment options, fostering the growth of this specific healthcare market. Advocacy from organizations suchs as the Spanish Society of Ophthalmology emphasizes the importance of adequate resources for eye health, which further supports the demand for AMD therapies and ensures sustainable market growth. ### **Advancements in Treatment Modalities** Technological innovations and research breakthroughs are adding momentum to the Spain Dry Age-Related Macular Degeneration (AMD) Market Industry. Recent advancements in treatment modalities, including the development of novel therapeutics and minimally invasive surgical techniques, have transformed AMD care. Clinical trials conducted by notable institutions in Spain have demonstrated positive results with new drug candidates that aim to slow the progression of AMD. For instance, the Spanish Agency of Medicines and Medical Devices reports that innovative drugs hold promise, leading to a rise in prescriptions and boosting the market. This progression in treatment technology can result in improved patient outcomes and increased demand for AMD solutions, further driving market growth. ### **Growing Awareness and Screening Programs** Increasing awareness regarding AMD and its impact on visual health is a crucial driver in the Spain Dry Age-Related Macular Degeneration (AMD) Market Industry. Ongoing initiatives from organizations like the Spanish Association of Patients with AMD are focusing on educating the public about the importance of early detection and regular eye screenings. A significant 60% of patients remain uninformed about AMD and its repercussions, which is why educational campaigns supported by the Spanish government are essential for promoting regular eye examinations among older adults. This rising awareness leads to higher screening rates and potential early intervention, which can enhance treatment success and stimulate growth in the AMD market sector. ## **Spain Dry Age-Related Macular Degeneration (AMD) Market Segment Insights** ### **Dry Age-Related Macular Degeneration (AMD) Market Stage Insights** The Spain Dry Age-Related Macular Degeneration (AMD) Market, particularly regarding the Stage segmentation, reveals a multifaceted landscape driven by the increasing prevalence of age-related ocular conditions among the aging population. The ongoing demographic shifts in Spain, marked by an increasing number of individuals aged 65 and above, are expected to further catalyze the growth of this market segment. As one of the key contributors to visual impairment in older adults, early age-related macular degeneration represents a crucial starting point for effective intervention. Identifying this stage allows for timely management and proactive measures, which can significantly improve a patient’s quality of life and slow disease progression. Moreover, the intermediate age-related macular degeneration stage is characterized by noticeable vision changes that often prompt patients to seek medical attention, subsequently creating opportunities for advances in treatment options and patient education programs. With the market focusing on early detection and personalized treatment plans, the demand for diagnostic tools and therapeutic solutions is anticipated to increase, ultimately supporting the overall market growth in Spain. Lastly, the late age-related macular degeneration stage often results in significant vision loss, emphasizing the need for robust healthcare strategies and societal awareness initiatives to assist affected individuals. The late stage often demands more complex interventions, underscoring the importance of healthcare policies that address patient needs and support long-term care. The combination of these factors illustrates the variety and significance of the Stage segmentation within the Spain Dry Age-Related Macular Degeneration (AMD) Market, reflecting mandatory trends toward improving patient outcomes and meeting the growing demands of an aging population while ensuring access to necessary medical resources. The integral role of government support and healthcare investments in combating AMD also shapes the market dynamics. Healthcare reforms aimed at increasing affordability and accessibility to eye care services are essential in empowering patients at all stages of the disease, further catalyzing the development of innovative therapies within the Spain Dry Age-Related Macular Degeneration (AMD) Market. Ultimately, the insights derived from this market segmentation will serve as a guiding framework for stakeholders aiming to enhance service delivery, promote preventative measures, and support clinical advancements in AMD management in Spain. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Dry Age-Related Macular Degeneration (AMD) Market Age Group Insights** The Spain [Dry Age-Related Macular Degeneration (AMD) Market](../../../reports/dry-age-related-macular-degeneration-amd-market-10657) exhibits a significant emphasis on age group segmentation, particularly as the population ages. Individuals above 75 years comprise a critical segment, given that they experience age-related health conditions, including AMD, at higher rates. This age group is crucial as it often leads to a greater demand for healthcare services and interventions, which translates to an increased focus on treatment options available for AMD. Following closely, those above 60 years represent another major demographic, characterized by heightened awareness and a growing desire to maintain their quality of life as they age. This segment is particularly focused on preventive measures and early intervention strategies. Additionally, the age group above 40 years is increasingly relevant, as proactive health monitoring begins in this bracket. As lifestyle factors and genetic predispositions contribute to the development of AMD, this age group plays an essential role in market growth, driven by rising health consciousness and the pursuit of innovative treatment options. With a steadily aging population, the trends in the Spain Dry Age-Related Macular Degeneration (AMD) Market suggest a robust need for targeted healthcare solutions and advancements in therapy for each age group effectively. ### **Dry Age-Related Macular Degeneration (AMD) Market Diagnosis and Treatment Insights** The Spain Dry Age-Related Macular Degeneration (AMD) Market within the Diagnosis and Treatment segment is experiencing notable growth, driven by an increasing aging population and rising awareness about eye health. The focal importance of treatment options in this market stems from the need for effective management strategies, as Dry AMD significantly affects the quality of life. With government initiatives supporting vision health, healthcare providers are expanding access to advanced treatments, fostering innovation in therapies and diagnostic technologies. Diagnosis plays a crucial role in early intervention, enabling timely management and reducing the impact of the disease. The segment's strength is evident as it addresses a growing patient base and engages in research efforts to develop new diagnostic tools, enhancing accuracy and efficiency. This focus on patient-centric solutions is indicative of the Spain Dry Age-Related Macular Degeneration (AMD) Market's commitment to improving outcomes and meeting the evolving demands of both patients and healthcare professionals. Overall, the segment is poised for growth, propelled by advancements in treatment modalities and a deeper understanding of Dry AMD, supporting a more informed approach to prevention and management within the healthcare system in Spain. ### **Dry Age-Related Macular Degeneration (AMD) Market Route of Administration Insights** The Route of Administration segment within the Spain Dry Age-Related Macular Degeneration (AMD) Market plays a crucial role in determining treatment efficacy and patient compliance. Oral medications have gained attention due to their ease of use, offering a non-invasive alternative that increases patient adherence to treatment regimens. This is particularly important in a country like Spain, where an aging population presents a growing demographic of AMD patients. On the other hand, injectables remain significant in this market, providing targeted therapy through intravitreal injections that directly influence the affected area. The preference for injectables often stems from their ability to achieve rapid therapeutic effects, which is critical for managing disease progression in AMD patients. The increasing incidence of AMD in Spain fosters a competitive landscape in the administration routes, leading to innovations and advancements in drug formulation and delivery systems. Overall, the combination of oral and injectable routes enhances treatment options and reflects the evolving landscape of the Spain Dry Age-Related Macular Degeneration (AMD) Market. ### **Dry Age-Related Macular Degeneration (AMD) Market End Users Insights** The Spain Dry Age-Related Macular Degeneration (AMD) Market demonstrates a diverse composition of End Users, encompassing hospitals clinics, diagnostic centers, and academic research institutes. Hospitals and clinics play a vital role by providing foundational patient care and specialized AMD treatment, which drives patient outreach and awareness. Diagnostic centers significantly contribute to early detection, enhancing treatment outcomes for AMD, thereby emphasizing the importance of timely interventions. Academic and research institutes are instrumental in advancing AMD knowledge, fostering innovations that improve diagnostic techniques and therapeutic options, ultimately benefiting the healthcare landscape. These segments collectively serve as the backbone of the AMD market in Spain, reflecting a well-structured approach to managing a growing patient population affected by AMD, driven by demographic shifts and an increasing emphasis on eye health. This strategic alignment among different End Users not only underscores their importance in the market but also highlights collaborative opportunities for advancing treatment methodologies and patient education. The significance of these segments is further underpinned by ongoing research initiatives and public health campaigns aimed at enhancing awareness and access to care for the aging population in Spain. ## **Spain Dry Age-Related Macular Degeneration (AMD) Market Key Players and Competitive Insights** The Spain Dry Age-Related Macular Degeneration (AMD) Market is characterized by a competitive landscape that is rapidly evolving, driven by advancements in treatment options, awareness programs, and an increasing patient population. Companies operating within this market are focused on developing innovative therapies aimed at addressing the needs of AMD patients while dealing with the challenges of regulatory compliance and market entry barriers. The landscape features a blend of large pharmaceutical enterprises and specialized biotechnology firms that are actively investing in research and development to bolster their product pipelines and enhance their market share. The competitive dynamics are influenced by factors such as pricing strategies, distribution channels, partnerships, and collaborations, all aimed at improving patient outcomes and gaining a foothold in this lucrative sector. Horizon Therapeutics has established a significant presence in the Spain Dry Age-Related Macular Degeneration (AMD) Market, leveraging its expertise in rare diseases and high unmet medical needs to cater to the AMD patient population effectively. The company boasts a robust portfolio of treatments that enhance its competitive edge while contributing to improved patient management and therapeutic outcomes. Horizon Therapeutics places a strong emphasis on research and clinical trials, thereby showcasing its commitment to innovation and comprehensive care strategies. This focus on cutting-edge research facilitates the development of tailored treatments for AMD, positioning the company as a key player within the Spanish market. Moreover, its strategic partnerships with healthcare professionals and advocacy groups help in raising awareness and improving access to treatments for patients suffering from dry AMD. Avanir Pharmaceuticals, while focusing primarily on patients with neurological disorders, has also started to make strides within the Spain Dry Age-Related Macular Degeneration (AMD) Market. The company is recognized for its innovative therapeutic solutions that address various challenges faced by AMD patients, particularly in enhancing the quality of vision and managing associated symptoms. Avanir Pharmaceuticals’ key products include treatments that have shown efficacy in improving patient outcomes. The company continues to explore strategic collaborations and potential mergers to expand its market footprint in Spain, thereby fortifying its position in the AMD landscape. This strategy not only broadens their service offerings but also enables them to tap into new segments of the market, reaffirming their commitment to advancing healthcare solutions for patients in need. Through focused investments and collaboration initiatives, Avanir Pharmaceuticals aims to contribute significantly to the improvement of AMD care in Spain. ### **Key Companies in the Spain Dry Age-Related Macular Degeneration (AMD) Market Include** - Horizon Therapeutics - Avanir Pharmaceuticals - **[Genentech](https://www.gene.com/patients/disease-education/age-related-macular-degeneration)** - Oxurion - AGTC - Bausch Health Companies - Sivantos - Roche - Novartis - Santen Pharmaceutical - Alimera Sciences - Eyenovia - Regeneron Pharmaceuticals - Apellis Pharmaceuticals ## **Spain Dry Age-Related Macular Degeneration (AMD) Market Industry Developments** In the Spain Dry Age-Related Macular Degeneration (AMD) Market, recent developments highlight significant activity among key players such as Horizon Therapeutics, Avanir Pharmaceuticals, Genentech, and Regeneron Pharmaceuticals. Growth in market valuation has been observed, particularly with reports in June 2023 indicating increased investments in research and development from companies like Roche and Novartis aimed at advancing treatment options. Current affairs show a heightened focus on innovative therapies, with Alimera Sciences and Eyenovia enhancing their research collaborations to expedite product development. Notably, in April 2023, Genentech's advancement in clinical trials for new AMD therapies has heightened competition in the Spanish market, further encouraging investment. Additionally, a merger in May 2023 involving Bausch Health Companies and another key player has drawn attention, reflecting consolidation trends within the industry. Over the past two to three years, significant governmental initiatives have emerged in Spain to combat AMD, including increased funding for eye care research, which has positively influenced stakeholder engagement and market dynamics. The growing prevalence of AMD in the aging population of Spain emphasizes the urgent need for effective therapies and enhances the market's potential for growth and innovation. ## **Spain Dry Age-Related Macular Degeneration (AMD) Market Segmentation Insights** ### **Dry Age-Related Macular Degeneration (AMD) Market Stage Outlook** - Early Age-Related Macular Degeneration - Intermediate Age-Related Macular Degeneration - Late Age-Related Macular Degeneration ### **Dry Age-Related Macular Degeneration (AMD) Market Age Group Outlook** - Above 75 years - Above 60 years - Above 40 years ### **Dry Age-Related Macular Degeneration (AMD) Market Diagnosis and Treatment Outlook** - Treatment - Diagnosis ### **Dry Age-Related Macular Degeneration (AMD) Market Route of Administration Outlook** - Oral - Injectables ### **Dry Age-Related Macular Degeneration (AMD) Market End Users Outlook** - Hospitals - Clinics - Diagnostic Centers - Academic Research Institutes ## Market Drivers ### Aging Population in Spain The demographic shift towards an aging population in Spain appears to be a primary driver for the Spain [Dry Age Related Macular Degeneration Amd](https://www.marketresearchfuture.com/reports/dry-age-related-macular-degeneration-amd-market-10657) Market. As the population ages, the incidence of age-related diseases, including dry AMD, is likely to increase. According to the Instituto Nacional de Estadistica, the percentage of individuals aged 65 and older is projected to rise significantly, reaching approximately 25% by 2030. This demographic trend suggests a growing patient base for dry AMD treatments and interventions. Consequently, healthcare providers and pharmaceutical companies may focus on developing targeted therapies and preventive measures to address the needs of this aging demographic. The increasing prevalence of dry AMD among older adults in Spain could lead to heightened demand for specialized eye care services and innovative treatment options, thereby driving market growth. ### Rising Healthcare Expenditure The rising healthcare expenditure in Spain is likely to contribute positively to the Spain Dry Age Related Macular Degeneration Amd Market. As the government and private sectors invest more in healthcare, there is an increasing focus on specialized treatments for chronic conditions, including dry AMD. According to the Ministry of Health, healthcare spending in Spain has been on an upward trajectory, with a notable increase in funding for ophthalmology services. This trend suggests that more resources will be allocated to the diagnosis and treatment of dry AMD, potentially leading to the development of new therapies and improved patient care. Furthermore, as healthcare budgets expand, there may be greater opportunities for collaboration between pharmaceutical companies and healthcare providers, facilitating the introduction of innovative solutions to address the needs of patients suffering from dry AMD. ### Government Initiatives and Funding Government initiatives and funding aimed at addressing eye health issues are likely to play a crucial role in the Spain Dry Age Related Macular Degeneration Amd Market. The Spanish government has recognized the growing burden of visual impairment due to age-related conditions and has implemented various health policies to improve access to eye care services. For instance, the National Health System (SNS) has allocated resources to enhance screening programs and public awareness campaigns about dry AMD. Additionally, funding for research and development of new treatment modalities is expected to increase, fostering innovation in the field. These initiatives may lead to improved patient access to cutting-edge therapies and better overall management of dry AMD, thereby stimulating market growth. The collaboration between public health authorities and private sector stakeholders could further enhance the effectiveness of these efforts. ### Growing Interest in Preventive Care The growing interest in preventive care among the Spanish population appears to be influencing the Spain Dry Age Related Macular Degeneration Amd Market. As awareness of the importance of eye health increases, individuals are more likely to seek regular eye examinations and adopt lifestyle changes that may mitigate the risk of developing dry AMD. Public health campaigns promoting eye health and the benefits of early detection are becoming more prevalent, encouraging proactive engagement with healthcare providers. This shift towards preventive care may lead to an increase in the number of patients diagnosed with early-stage dry AMD, creating a demand for monitoring and treatment options. Additionally, the emphasis on preventive measures could drive innovation in the development of supplements and therapies aimed at reducing the risk of progression to advanced stages of the disease, thereby shaping the future landscape of the dry AMD market in Spain. ### Advancements in Diagnostic Technologies Recent advancements in diagnostic technologies are likely to enhance the detection and management of dry AMD in Spain. The Spain Dry Age Related Macular Degeneration Amd Market is experiencing a shift towards more sophisticated imaging techniques, such as optical coherence tomography (OCT) and fundus autofluorescence. These technologies enable earlier diagnosis and more accurate monitoring of disease progression, which is crucial for effective treatment planning. As healthcare providers adopt these advanced diagnostic tools, the potential for timely intervention increases, thereby improving patient outcomes. Furthermore, the integration of artificial intelligence in diagnostic processes may streamline workflows and enhance the accuracy of assessments. This trend suggests that the market for dry AMD treatments in Spain could expand as more patients are diagnosed and treated at earlier stages of the disease, ultimately leading to a more proactive approach in managing dry AMD. ## Future Outlook The Dry Age Related Macular Degeneration market in Spain is projected to grow at a 7.52% CAGR from 2025 to 2035, driven by increasing aging population and advancements in treatment options. **New opportunities:** - Development of telemedicine platforms for remote patient monitoring - Investment in AI-driven diagnostic tools for early detection - Expansion of personalized treatment plans based on genetic profiling By 2035, the market is expected to be robust, driven by innovation and increased patient access. ## Segment Insights ### By Application: Clinical Diagnosis (Largest) vs. Research and Development (Fastest-Growing) In the Spain Dry [Age Related Macular Degeneration](https://www.marketresearchfuture.com/reports/age-related-macular-degeneration-market-5736) (AMD) Market, the application segment is primarily dominated by Clinical Diagnosis, which accounts for the largest share. The increasing prevalence of AMD among the aging population drives a consistent demand for effective clinical diagnosis tools and techniques. In parallel, Research and Development stands out due to its innovative approaches, aiming to enhance therapeutic interventions and diagnostic accuracy, capturing a significant portion of the market. Clinical Diagnosis (Dominant) vs. Research and Development (Emerging) Clinical Diagnosis serves as the backbone of the Spain AMD market, providing essential tools and methodologies for timely detection and management of the disease. Its dominant position is reinforced by advancements in diagnostic technologies and a growing emphasis on early intervention. Conversely, Research and Development is emerging as a critical segment, fueled by innovative research initiatives and funding aimed at discovering new treatment modalities. This segment is characterized by intense collaboration between research institutions and pharmaceutical companies, potentially leading to breakthroughs that can reshape the market. ### By Treatment Type: Pharmacological Therapy (Largest) vs. Nutritional Supplements (Fastest-Growing) In the Spain Dry Age Related Macular Degeneration (AMD) market, the 'Treatment Type' segment exhibits a diverse distribution, with Pharmacological Therapy commanding the largest share. This segment encompasses various medications specifically aimed at slowing the progression of AMD. Conversely, Nutritional Supplements are rapidly gaining traction, reflecting a growing consumer shift towards preventative health measures and holistic treatment options. Surgical Interventions, while significant, hold a smaller segment of the market compared to these two treatment methods, indicating a clear preference for less invasive options among patients. Current trends within the Treatment Type segment are driven by increasing awareness of AMD and advances in therapeutic options. The expansion of Pharmacological Therapy options is encouraging more patients to seek treatment, thus bolstering its market dominance. Meanwhile, Nutritional Supplements are emerging as a viable alternative, fueled by demographic shifts and the aging population in Spain, enhancing their growth as more consumers prioritize eye health and preventive care. Pharmacological Therapy (Dominant) vs. Nutritional Supplements (Emerging) Pharmacological Therapy is recognized as the dominant treatment approach in the Spain Dry Age Related Macular Degeneration market, attributed to its established efficacy in slowing disease progression through targeted interventions. This segment's deep-rooted presence is supported by a range of medications that cater to various stages of AMD, appealing to both patients and healthcare providers. Conversely, Nutritional Supplements represent an emerging facet of treatment, capitalizing on the growing trend of natural health solutions. These supplements are designed to provide essential vitamins and minerals that support eye health, appealing particularly to health-conscious consumers. Together, these segments underline the evolving treatment landscape, emphasizing patient preferences for both effective medical and preventive approaches. ### By Patient Demographics: Age Group (Largest) vs. Gender (Fastest-Growing) In the Spain Dry Age Related Macular Degeneration (AMD) market, the age group segment showcases a significant distribution, with seniors aged 65 years and above holding the largest market share. This demographic is particularly susceptible to AMD, resulting in a concentrated demand for treatment and services aimed at this age group. Meanwhile, the gender demographic reveals an emerging trend, with women showing a faster growth rate in diagnosis and treatment uptake, likely due to longer life expectancy and increased awareness of eye health issues. Age Group: 65+ (Dominant) vs. Gender: Women (Emerging) The age group of 65 years and older is the dominant segment within the Spain Dry AMD market, primarily due to the higher prevalence of age-related macular degeneration in older adults. This demographic drives significant demand for healthcare services, specialized treatments, and consultation. On the other hand, the female gender is emerging as a crucial market driver, as studies indicate that women are more frequently diagnosed with AMD than men. This trend underscores the importance of targeted marketing and educational initiatives aimed at women, helping to improve awareness and encourage earlier intervention strategies. ### By Disease Stage: Intermediate Stage (Largest) vs. Advanced Stage (Fastest-Growing) In the Spain Dry Age Related Macular Degeneration (AMD) market, the disease stage segments reveal a compelling distribution with 'Intermediate Stage' leading the market as the largest segment. This stage accounts for a substantial proportion of diagnosed cases, reflecting the prevalence of AMD in individuals who are showing noticeable symptoms but have not yet progressed to advanced stages. 'Advanced Stage', while smaller in share, represents a rapidly expanding segment as it is associated with severe vision impairments and necessitates immediate therapeutic intervention, contributing to its growth dynamics. Intermediate Stage (Dominant) vs. Advanced Stage (Emerging) The 'Intermediate Stage' of Dry AMD is characterized by the presence of drusen, which are yellow deposits beneath the retina, as well as pigmentary changes, making it the dominant segment in the Spain market. Patients in this stage often do not exhibit significant vision problems, but regular monitoring is crucial. Conversely, the 'Advanced Stage' presents a more severe form of the disease, with occurring wet or dry types leading to significant vision loss. This stage is emerging rapidly due to increased recognition and the pressing need for treatment, hence attracting more research and development efforts. The clinical urgency associated with advanced AMD drives its market share rise, establishing it as a focal point for newer therapeutic solutions. ## Competitive Benchmarking The Dry Age Related Macular Degeneration Amd Market in Spain is characterized by a competitive landscape that is increasingly shaped by innovation and strategic partnerships. Key players such as Novartis (Switzerland), Regeneron Pharmaceuticals (USA), and Roche (Switzerland) are actively engaged in enhancing their market positions through a combination of research and development, mergers and acquisitions, and regional expansions. These companies appear to be focusing on developing novel therapies and improving patient access to existing treatments, which collectively fosters a dynamic environment that encourages competition and drives growth. In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market structure is moderately fragmented, with several players vying for market share. This fragmentation allows for a diverse range of products and services, but it also means that companies must continuously innovate to maintain their competitive edge. The collective influence of these key players is significant, as they set trends that smaller companies often follow, thereby shaping the overall market dynamics. In December 2025, Novartis (Switzerland) announced a strategic partnership with a leading Spanish research institution to accelerate the development of gene therapies for AMD. This collaboration is expected to leverage cutting-edge research and local expertise, potentially leading to breakthroughs in treatment options. Such partnerships not only enhance Novartis's R&D capabilities but also position the company as a leader in innovative solutions tailored to the needs of the Spanish market. In November 2025, Regeneron Pharmaceuticals (USA) launched a new clinical trial in Spain aimed at evaluating the efficacy of its latest AMD treatment. This trial is significant as it underscores Regeneron's commitment to advancing therapeutic options and demonstrates its proactive approach to addressing unmet medical needs. The outcomes of this trial could have substantial implications for the company's market share and reputation in the region. In October 2025, Roche (Switzerland) expanded its distribution network in Spain by partnering with local pharmacies to improve patient access to its AMD therapies. This strategic move is indicative of Roche's focus on enhancing patient engagement and ensuring that its products are readily available. By strengthening its distribution channels, Roche is likely to improve its competitive positioning and foster brand loyalty among healthcare providers and patients alike. As of January 2026, current trends in the Dry Age Related Macular Degeneration Amd Market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in treatment development. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation. Looking ahead, competitive differentiation is expected to evolve, with a shift from price-based competition to a focus on technological advancements, innovative therapies, and reliable supply chains. This transition may ultimately enhance patient outcomes and reshape the market landscape. ## Recent News & Developments In the Spain Dry Age-Related Macular Degeneration (AMD) Market, recent developments highlight significant activity among key players such as Horizon Therapeutics, Avanir Pharmaceuticals, Genentech, and Regeneron Pharmaceuticals. Growth in market valuation has been observed, particularly with reports in June 2023 indicating increased investments in research and development from companies like Roche and Novartis aimed at advancing treatment options. Current affairs show a heightened focus on innovative therapies, with Alimera Sciences and Eyenovia enhancing their research collaborations to expedite product development. Notably, in April 2023, Genentech's advancement in clinical trials for new AMD therapies has heightened competition in the Spanish market, further encouraging investment. Additionally, a merger in May 2023 involving Bausch Health Companies and another key player has drawn attention, reflecting consolidation trends within the industry. Over the past two to three years, significant governmental initiatives have emerged in Spain to combat AMD, including increased funding for eye care research, which has positively influenced stakeholder engagement and market dynamics. The growing prevalence of AMD in the aging population of Spain emphasizes the urgent need for effective therapies and enhances the market's potential for growth and innovation. ## Report Scope | MARKET SIZE 2024 | 133.28(USD Million) | | --- | --- | | MARKET SIZE 2025 | 144.34(USD Million) | | MARKET SIZE 2035 | 295.96(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.52% (2024 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Novartis (ES), Regeneron Pharmaceuticals (ES), Roche (ES), Bayer (ES), Allergan (ES), Apellis Pharmaceuticals (ES), Santen Pharmaceutical (ES), Zeiss (ES), Hoya Corporation (ES) | | Segments Covered | Application, Treatment Type, Patient Demographics, Disease Stage | | Key Market Opportunities | Emerging telemedicine solutions enhance patient access to treatments in the Spain Dry Age Related Macular Degeneration Amd Market. | | Key Market Dynamics | Rising demand for innovative therapies drives competition in Spain's Dry Age Related Macular Degeneration market. | | Countries Covered | Spain | ## Frequently Asked Questions **Q: What is the current market valuation of the Spain Dry Age Related Macular Degeneration AMD market?** A: The market valuation was 133.28 USD Million in 2024. **Q: What is the projected market size for the Spain Dry Age Related Macular Degeneration AMD market by 2035?** A: The projected valuation for 2035 is 295.96 USD Million. **Q: What is the expected CAGR for the Spain Dry Age Related Macular Degeneration AMD market during the forecast period?** A: The expected CAGR for the market from 2025 to 2035 is 7.52%. **Q: Which companies are the key players in the Spain Dry Age Related Macular Degeneration AMD market?** A: Key players include Novartis, Regeneron Pharmaceuticals, Roche, Bayer, Allergan, Apellis Pharmaceuticals, Santen Pharmaceutical, Zeiss, and Hoya Corporation. **Q: How is the Spain Dry Age Related Macular Degeneration AMD market segmented by application?** A: The market is segmented into Clinical Diagnosis, Research and Development, and Patient Monitoring, with valuations ranging from 40.0 to 120.0 USD Million. **Q: What are the treatment types available in the Spain Dry Age Related Macular Degeneration AMD market?** A: Treatment types include Pharmacological Therapy, Surgical Intervention, and Nutritional Supplements, with valuations from 33.28 to 135.0 USD Million. **Q: How does the market segment by patient demographics in Spain?** A: The market segments by Age Group, Gender, and Socioeconomic Status, with valuations ranging from 20.0 to 90.0 USD Million. **Q: What stages of the disease are recognized in the Spain Dry Age Related Macular Degeneration AMD market?** A: The disease stages include Early Stage, Intermediate Stage, and Advanced Stage, with valuations from 43.28 to 120.0 USD Million. **Q: What trends are influencing the growth of the Spain Dry Age Related Macular Degeneration AMD market?** A: Trends include advancements in treatment options and increasing awareness, contributing to the projected growth rate. **Q: How does the market performance in Spain compare to other regions?** A: While specific regional comparisons are not provided, the growth potential in Spain appears robust, driven by key players and increasing market demand. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/spain-dry-age-related-macular-degeneration-market-44902*